News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–18
Matches
18
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

18 matching headlines

Ticker or company: ONCYMain company stories
Clear
Latest

MarketBeat Earnings

Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Oncolytics Biotech (NASDAQ:ONCY) reported a quarterly loss of $0.08 per share, missing analysts' consensus estimate of a $0.05 loss by $0.03. Despite the earnings miss, the stock rose 0.5% to $0.82, and institutional investors have been increasing their holdings. Analysts currently rate the stock a "Moderate Buy" with an average price target of $8.50, as the company continues …

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingView Earnings Main company 🇺🇸 United States

ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources

Oncolytics Biotech Inc. (ONCY) reported a widened net loss of $9.4 million in Q2 2026, attributed to rising R&D and G&A expenses due to clinical trial expansion and increased stock-based compensation. While current cash is sufficient for near-term milestones, the company will require additional …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Oncolytics Biotech Inc (ONCY) has an earnings forecast score of 7.67, ranking 274 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.25 for ONCY, with a high of $10.00 and a low of $3.00, …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Analyst action Main company 🇺🇸 United States

Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

Oncolytics Biotech (ONCY) is scheduled to release its Q2 2026 earnings after market close on Friday, August 14th, with analysts forecasting a loss of $0.0538 per share. The company previously missed consensus estimates, reporting a $0.08-per-share loss. ONCY shares opened at $0.80, and the …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report

This article provides the 10-Q report for Oncolytics Biotech for the first quarter of 2026. The content is a placeholder, indicating that the full financial document is intended to be included.

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Oncolytics Biotech Inc (ONCY), stating its current financial score is 6.34 and ranks 258 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is considered stable, though its operating efficiency is …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

ONCY|Oncolytics Biotech Inc|Price:0.750|Chg%:-0.042

This article provides a comprehensive stock analysis of Oncolytics Biotech Inc (ONCY), highlighting its healthy fundamentals, high growth potential, and "Buy" ratings from multiple analysts despite a recent weak stock market performance. The company is developing pelareorep, an immunotherapeutic agent for various cancers, and …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Oncolytics Biotech Inc (ONCY). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page presents general stock information for ONCY, including its market …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice

Oncolytics Biotech Inc. (ONCY) was granted FDA Fast Track designation for pelareorep in combination with a checkpoint inhibitor for 2L+ squamous cell anal cancer, based on promising results from the GOBLET study. Despite this positive development, the company received a Nasdaq compliance notice for …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Oncolytics Biotech Inc (ONCY) shareholder structure, detailing major individual and institutional holdings. It includes a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity. Key individual shareholders like Kirk J Look and Thomas …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Oncolytics Biotech (ONCY) received a notice from Nasdaq on July 20, 2026, indicating its failure to maintain the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until January 19, 2027, to regain compliance, …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Market update Main company 🇺🇸 United States

Oncolytics Biotech gets Nasdaq notice for failing $1 minimum bid price rule

Oncolytics Biotech has received a Nasdaq notice due to its stock (ONCY) failing to maintain a $1 minimum bid price for 30 consecutive trading sessions. The company has been given a 180-day period, ending January 19, 2027, to regain compliance by having its stock …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

ONCY Q2'26 Earnings: revenue estimate is 0 USD

Oncolytics Biotech Inc. (ONCY) is scheduled to release its Q2'26 earnings on July 31. The company is expected to report 0 USD in revenue and an EPS of (0.05) USD for the quarter. This article provides a brief overview of the upcoming earnings and …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Market update Main company 🇺🇸 United States

Stocks in play: Oncolytics Biotech Inc

Oncolytics Biotech Inc (N.ONCY) has received Fast Track designation from the U.S. Food and Drug Administration for pelareorep combined with a checkpoint inhibitor. This designation is for treating inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal that has progressed on …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Canada Market update Main company 🇺🇸 United States

FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com

Oncolytics Biotech Inc. (NASDAQ: ONCY) has received Fast Track designation from the FDA for pelareorep combined with a checkpoint inhibitor to treat inoperable, recurrent, or metastatic anal canal squamous cell carcinoma. This designation accelerates development and review for therapies addressing serious diseases with unmet …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Investigational anal cancer therapy posts 30% response rate

Oncolytics Biotech (Nasdaq: ONCY) has received U.S. FDA Fast Track designation for pelareorep in combination with a checkpoint inhibitor for the treatment of advanced anal cancer. This designation is based on encouraging data from the GOBLET study, which showed an objective response rate of …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Oncolytics receives FDA Fast Track for pelareorep plus checkpoint inhibitor in second-line+ anal cancer

Oncolytics Biotech (ONCY) has secured FDA Fast Track designation for its drug pelareorep combined with a checkpoint inhibitor for treating advanced squamous cell carcinoma of the anal canal (SCAC). This designation is based on promising data from the GOBLET study, which showed a 30% …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Market update Main company 🇺🇸 United States

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Oncolytics Biotech has received Fast Track designation from the FDA for its immunotherapy pelareorep, combined with a checkpoint inhibitor, to treat advanced anal cancer that has progressed after first-line therapy. This marks the third Fast Track designation for pelareorep in gastrointestinal cancers, highlighting its …

ONCY main company
Sharemaestro market context Price below Trend Line 52 weeks -17.4% · Next-week setup negative 35.3% ONCY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context